Big-pharma stocks have generally had an outstanding week thus far. Through Thursday's closing bell, Bristol Myers Squibb (NYSE: BMY) shares have tracked higher by a respectable 8.2%, Pfizer (NYSE: PFE) stock is up by an eye-popping 17.5%, and Eli Lilly (NYSE: LLY) has seen its equity rise by a healthy 14.6%, according to data from market Intelligence - opens in new tab" data-saferedirecturl="https://www.google.com/url?q=http://marketintelligence.spglobal.com/&source=gmail&ust=1635619496054000&usg=AFQjCNGx-1GD8GFpoWSPkyjyJJvP_y5W5w" data-uw-rm-brl="false" data-uw-rm-ext-link="" data-uw-rm-kbnav="ble" data-uw-styling-context="true" href="http://marketintelligence.spglobal.com/" target="_blank"> S&P Global Market Intelligence .
As a result, Pfizer and Lilly's shares are both trading close to their 52-week highs right now, while Bristol's stock has regained a fair amount of lost ground after trending lower for most of 2021. These three elite pharma stocks have raced higher this week due to a mix of market-wide and company-specific factors.
Image source: Getty Images.
For further details see:
Here's Why Shares of Bristol Myers Squibb, Eli Lilly, and Pfizer Rocketed Higher This Week